title: Pharmacokinetics of caspofungin increased dosage in a patient on rifampin-containing anti-tubercular treatment.
abstract: We describe a patient treated with caspofungin and rifampin; after increasing the dosage of the former (70 mg/day) we observed an unexpectedly lower plasma exposure (AUC0-24 79.5 μg/ml*h vs. 108.8 μg/ml*h). Although rifampin-mediated complete enzyme induction may take longer than 2 weeks, the clinical advantage of an increased caspofungin dose deserves clinical investigation.
authors.affiliation: From the Unit of Infectious Diseases, Department of Medical Sciences, University of Torino , Torino , Italy.
authors.forename: Andrea
authors.initials: A
authors.lastname: Calcagno
authors.forename: Lorena
authors.initials: L
authors.lastname: Baietto
authors.forename: Nicole
authors.initials: N
authors.lastname: Pagani
authors.forename: Roberto
authors.initials: R
authors.lastname: Bertucci
authors.forename: Roberto
authors.initials: R
authors.lastname: Rostagno
authors.forename: Antonio
authors.initials: A
authors.lastname: D'Avolio
authors.forename: Giovanni
authors.initials: G
authors.lastname: Di Perri
authors.forename: Francesco Giuseppe
authors.initials: FG
authors.lastname: De Rosa
mesh_terms: D000935:Antifungal Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D000995:Antitubercular Agents / Q000008:administration & dosage*; D000077336:Caspofungin; D004347:Drug Interactions; D054714:Echinocandins / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D006801:Humans; D055666:Lipopeptides; D008297:Male; D008875:Middle Aged; D010949:Plasma / Q000737:chemistry; D012293:Rifampin / Q000008:administration & dosage*
chemical_list: D000935:Antifungal Agents; D000995:Antitubercular Agents; D054714:Echinocandins; D055666:Lipopeptides; D000077336:Caspofungin; D012293:Rifampin